Emtricitabine: all 177 studies that test it

Page 1 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingNCT07792096Phase 3
• Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingNCT07708727Phase 2/3
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingNCT07678268Phase 4
• A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingNCT07645287Phase 2
• REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingNCT07476339Phase 4
• Antiviral Clinical Trial for Long Covid-19RecruitingNCT06511063Phase 2
• The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingNCT06375304Phase 4
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingNCT06337032Phase 4
• Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingNCT06133686Phase 3
• Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of ADRecruitingNCT04500847Phase 1
• Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)CompletedNCT06104306Phase 4Results posted
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingNCT05052996Phase 2Results posted
• Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionActive, not recruitingNCT04994509Phase 3Results posted
• Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based BiosensorCompletedNCT04870671Early Phase 1Results posted
• Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGWCompletedNCT04760691Phase 1Results posted
• Biomarkers for Event-driven PrEP AdherenceCompletedNCT04298697Phase 4Results posted
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVCompletedNCT04143594Phase 2Results posted
• Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone TherapyCompletedNCT04050371Phase 4Results posted
• Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usECompletedNCT03998176Phase 4Results posted
• Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersCompletedNCT03960645Phase 1Results posted
• Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI TractCompletedNCT03917420Phase 1Results posted
• Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/EmtricitabineCompletedNCT03836729Phase 1Results posted
• B/F/TAF Switch Study for HIV-HBV CoinfectionCompletedNCT03797014Phase 4Results posted
• Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsCompletedNCT03547908Phase 3Results posted
• B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected AdultsTerminatedNCT03532425Phase 4Results posted
• Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsCompletedNCT03405935Phase 3Results posted
• DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP AdherenceCompletedNCT03387462Phase 4Results posted
• ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-AdherenceCompletedNCT03218592Phase 4Results posted
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedCompletedNCT03110380Phase 3Results posted
• IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration ProjectCompletedNCT03058835Phase 4Results posted
• The Cellular Pharmacology of F-TAF in Dried Blood SpotsCompletedNCT02962739Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionTerminatedNCT02842086Phase 3Results posted
• Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentCompletedNCT02707601Phase 3Results posted
• Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedNCT02652624Phase 3Results posted
• Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedNCT02616783Phase 3Results posted
• Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICompletedNCT02616029Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607956Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607930Phase 3Results posted
• Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCompletedNCT02605954Phase 3Results posted
• Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedCompletedNCT02603120Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedNCT02600819Phase 3Results posted
• Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIVCompletedNCT02495779Not applicableResults posted
• Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCCompletedNCT02469246Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedNCT02431247Phase 3Results posted
• Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02397694Phase 2Results posted
• Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsCompletedNCT02276612Phase 2/3Results posted
• Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFCompletedNCT02121795Phase 3Results posted
• Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsCompletedNCT02071082Phase 3Results posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedNCT01967940Phase 3Results posted
• Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedNCT01818596Phase 3Results posted
• Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedNCT01815736Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01797445Phase 3Results posted
• A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention ServicesCompletedNCT01781806Phase 4Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01780506Phase 3Results posted
• FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral ReservoirCompletedNCT01777997Phase 4Results posted
• Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) ClinicsCompletedNCT01632995Not applicableResults posted
• Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively TreatedCompletedNCT01529749Phase 4Results posted
• Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenCompletedNCT01505114Phase 2Results posted
• Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01497899Phase 2Results posted
• Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected PatientsCompletedNCT01270802Phase 4Results posted
• HIV Persistence and Viral ReservoirsCompletedNCT01025427Phase 4Results posted
• Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIVCompletedNCT00949234Phase 2Results posted
• Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)CompletedNCT00928187Phase 3Results posted
• Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy WomenCompletedNCT00869960Phase 4Results posted
• Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to EmtricitabineCompletedNCT00743340Phase 2Results posted
• Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive SubjectsCompletedNCT00654147Phase 2Results posted
• Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected AdultsCompletedNCT00608569Not applicableResults posted
• Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis BTerminatedNCT00524173Phase 2Results posted
• Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 InfectionCompletedNCT00414518Not applicableResults posted
• Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected ChildrenCompletedNCT00364793Phase 1/2Results posted
• Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir DipivoxilCompletedNCT00307489Phase 2Results posted
• Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected SubjectsCompletedNCT00112047Phase 3Results posted
• Nine Month Course of Anti-HIV Medications for People Recently Infected With HIVTerminatedNCT00090779Phase 2Results posted
• Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsCompletedNCT00084136Phase 4Results posted
• Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV DrugsCompletedNCT00016718Phase 1/2Results posted
• A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)CompletedNCT07532304Phase 1
• Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore StudyActive, not recruitingNCT07210528Phase 1
• Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruitingNCT07055451Phase 1
• Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South AfricaActive, not recruitingNCT07006246Phase 4
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Active, not recruitingNCT06630286Phase 3
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingNCT06333808Phase 3
• Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)CompletedNCT06177574Phase 4
• Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South AfricaActive, not recruitingNCT06138600Phase 3
• UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for ChildrenCompletedNCT05993767Phase 2
• Project Engage: Oral PrEP AcceptabilityCompletedNCT05458765Phase 2
• Doravirine and Weight Gain in Antiretroviral NaiveWithdrawnNCT05457530Phase 3
• Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of AgeStatus unknownNCT05147740Phase 4
• Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 InfectionActive, not recruitingNCT05122754Phase 4
• A Study of JNJ-56136379 in Healthy ParticipantsWithdrawnNCT04853524Phase 1
• Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged HomeCompletedNCT04685512Phase 2/3
• A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate AgentsCompletedNCT04661397Phase 1
• Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender MenActive, not recruitingNCT04593680Not applicable
• Bictegravir/FTC/TAF for the Treatment of Primary HIV InfectionStatus unknownNCT04483674Phase 2
• Evaluation of Drug Interaction Between HS-10234 and EmtriccitabineCompletedNCT04477096Phase 1
• Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)CompletedNCT04388904Phase 4
• Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in ColombiaCompletedNCT04359095Phase 2/3
• Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare PersonnelCompletedNCT04334928Phase 3
• Accelerated PrEP Access for Black MSM and TWWithdrawnNCT04329442Not applicable
• Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsStatus unknownNCT04311957Phase 4

← Emtricitabine overview